PROTECT Post Hoc Analysis: Efficacy of Sparsentan vs Irbesartan in Patients With IgA Nephropathy ≤12 mo vs >12 mo From Kidney Biopsy
MA-SP-25-0214 | November 2025
Congress Materials
Explore our congress materials
Encore posters are re-presentations of previously published data.
Filter by:
Year
Year
×Event
Event
×Therapeutic area
Therapeutic area
×Disease area
Disease area
×Product
Product
×Study/Registry
Study/Registry
×Resource type
Resource type
×Filter by:
Year
Year
×Event
Event
×Therapeutic area
Therapeutic area
×Disease area
Disease area
×Product
Product
×Study/Registry
Study/Registry
×Resource type
Resource type
×Results167
Sort by
Spatial transcriptomics reveals sparsentan-associated remodelling of complement-active renal niches in IgAN
American Society of Nephrology (ASN) Kidney Week – 2026
The effect of Sparsentan on urine and plasma proteome of patients with IgAN– Findings from the SPARTAN study
American Society of Nephrology (ASN) Kidney Week – 2026
Natural History of Recurrent IgA Nephropathy after Kidney Transplantation: Findings from the UK National Registry of Rare Kidney Diseases (RaDaR)
American Society of Nephrology (ASN) Kidney Week – 2026
Urinary Biomarker Data From the PROTECT Study in IgA Nephropathy Demonstrate Renal Anti-Inflammatory Actions of Sparsentan, Including Reduced Macrophage, Complement, and B-Cell Activation Signals
American Society of Nephrology (ASN) Kidney Week – 2026
Urinary biomarker data fromthe PROTECT study in IgAnephropathy demonstrate renalanti-inflammatory actions of sparsentan, including reduced macrophage, complement, and B-cell activation signals
American Society of Nephrology (ASN) Kidney Week – 2026
The Association between Achievement of Low Proteinuria Thresholds and Health-Related Quality ofLife in Focal Segmental Glomerulosclerosis: Pooled DUET & DUPLEX Analysis
American Society of Nephrology (ASN) Kidney Week – 2026
Join the
Conversation
Sign up to receive updates on the latest news, resources, and data on rare disease research.
Connect with our MSL team today
Arrange a meeting with a member of our medical science liaison (MSL) team to discuss the latest insights, clinical trial data, and management trends.
Find your MSL